Pacira Other Current Liab vs Common Stock Total Equity Analysis

PCRX Stock

USD 28.57 0.55 1.89%

Pacira Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pacira Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pacira Pharmaceuticals is a good investment. Please check the relationship between Pacira Pharmaceuticals Other Current Liab and its Common Stock Total Equity accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.

Other Current Liab vs Common Stock Total Equity

Other Current Liab vs Common Stock Total Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pacira Pharmaceuticals Other Current Liab account and Common Stock Total Equity. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Pacira Pharmaceuticals' Other Current Liab and Common Stock Total Equity is 0.58. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Pacira Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pacira Pharmaceuticals' Other Current Liab and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Pacira Pharmaceuticals are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Other Current Liab i.e., Pacira Pharmaceuticals' Other Current Liab and Common Stock Total Equity go up and down completely randomly.

Correlation Coefficient

0.58

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Other Current Liab

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Most indicators from Pacira Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pacira Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.At this time, Pacira Pharmaceuticals' Tax Provision is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.33 in 2024, whereas Selling General Administrative is likely to drop slightly above 63.1 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	31.8M	40.0M	23.8M	16.1M
Depreciation And Amortization	13.6M	61.4M	75.6M	79.4M

Interest Expense Depreciation And Amortization

Pacira Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.79	0.68	0.96	0.8	0.92	0.22	0.95	0.32	0.58	0.65	0.98	0.84	0.56	0.97	0.78	0.96	0.61	0.65	0.36	0.98	0.94	0.72	0.84	0.92	0.92
Other Current Liab	0.79		0.69	0.68	0.87	0.8	-0.1	0.71	0.12	0.51	0.78	0.76	0.54	0.35	0.8	0.68	0.75	0.58	0.62	0.08	0.8	0.74	0.4	0.74	0.87	0.61
Total Current Liabilities	0.68	0.69		0.51	0.78	0.67	0.11	0.56	0.06	0.12	0.9	0.6	0.82	0.65	0.56	0.79	0.52	0.42	0.45	0.15	0.59	0.55	0.23	0.56	0.81	0.44
Total Stockholder Equity	0.96	0.68	0.51		0.66	0.87	0.22	0.91	0.38	0.6	0.48	0.96	0.76	0.47	0.93	0.66	0.98	0.6	0.66	0.39	0.93	0.96	0.8	0.81	0.79	0.98
Other Liab	0.8	0.87	0.78	0.66		0.77	-0.06	0.67	0.35	0.46	0.87	0.78	0.69	0.39	0.77	0.68	0.72	0.35	0.39	-0.07	0.79	0.69	0.43	0.61	0.88	0.62
Property Plant And Equipment Net	0.92	0.8	0.67	0.87	0.77		0.29	0.91	0.16	0.63	0.6	0.88	0.8	0.67	0.89	0.82	0.85	0.73	0.76	0.47	0.9	0.86	0.6	0.93	0.94	0.79
Current Deferred Revenue	0.22	-0.1	0.11	0.22	-0.06	0.29		0.28	-0.34	0.35	0.0	0.11	0.29	0.36	0.24	0.5	0.14	0.3	0.27	0.7	0.23	0.19	0.08	0.38	0.23	0.15
Net Debt	0.95	0.71	0.56	0.91	0.67	0.91	0.28		0.3	0.61	0.45	0.94	0.78	0.63	0.96	0.72	0.9	0.57	0.6	0.45	0.96	0.85	0.67	0.81	0.88	0.86
Retained Earnings	0.32	0.12	0.06	0.38	0.35	0.16	-0.34	0.3		0.04	0.08	0.46	0.34	0.16	0.29	-0.16	0.37	-0.34	-0.32	-0.42	0.31	0.25	0.4	-0.13	0.18	0.42
Accounts Payable	0.58	0.51	0.12	0.6	0.46	0.63	0.35	0.61	0.04		0.19	0.55	0.28	0.2	0.67	0.52	0.6	0.34	0.41	0.5	0.65	0.62	0.3	0.67	0.54	0.55
Cash	0.65	0.78	0.9	0.48	0.87	0.6	0.0	0.45	0.08	0.19		0.57	0.66	0.37	0.56	0.73	0.52	0.39	0.42	-0.05	0.59	0.55	0.29	0.52	0.78	0.43
Non Current Assets Total	0.98	0.76	0.6	0.96	0.78	0.88	0.11	0.94	0.46	0.55	0.57		0.78	0.5	0.96	0.65	0.98	0.53	0.58	0.23	0.97	0.93	0.76	0.76	0.87	0.94
Non Currrent Assets Other	0.84	0.54	0.82	0.76	0.69	0.8	0.29	0.78	0.34	0.28	0.66	0.78		0.81	0.72	0.8	0.71	0.44	0.46	0.39	0.75	0.69	0.55	0.65	0.83	0.72
Other Assets	0.56	0.35	0.65	0.47	0.39	0.67	0.36	0.63	0.16	0.2	0.37	0.5	0.81		0.48	0.68	0.38	0.34	0.34	0.56	0.51	0.39	0.22	0.53	0.66	0.35
Long Term Debt	0.97	0.8	0.56	0.93	0.77	0.89	0.24	0.96	0.29	0.67	0.56	0.96	0.72	0.48		0.74	0.94	0.58	0.61	0.34	1.0	0.89	0.71	0.82	0.9	0.88
Cash And Short Term Investments	0.78	0.68	0.79	0.66	0.68	0.82	0.5	0.72	-0.16	0.52	0.73	0.65	0.8	0.68	0.74		0.63	0.64	0.65	0.62	0.75	0.67	0.36	0.83	0.87	0.57
Net Receivables	0.96	0.75	0.52	0.98	0.72	0.85	0.14	0.9	0.37	0.6	0.52	0.98	0.71	0.38	0.94	0.63		0.59	0.66	0.28	0.95	0.97	0.78	0.79	0.81	0.97
Common Stock Total Equity	0.61	0.58	0.42	0.6	0.35	0.73	0.3	0.57	-0.34	0.34	0.39	0.53	0.44	0.34	0.58	0.64	0.59		0.98	0.55	0.57	0.65	0.5	0.88	0.61	0.56
Common Stock Shares Outstanding	0.65	0.62	0.45	0.66	0.39	0.76	0.27	0.6	-0.32	0.41	0.42	0.58	0.46	0.34	0.61	0.65	0.66	0.98		0.55	0.6	0.74	0.53	0.9	0.63	0.62
Short Term Investments	0.36	0.08	0.15	0.39	-0.07	0.47	0.7	0.45	-0.42	0.5	-0.05	0.23	0.39	0.56	0.34	0.62	0.28	0.55	0.55		0.33	0.35	0.15	0.63	0.32	0.3
Non Current Liabilities Total	0.98	0.8	0.59	0.93	0.79	0.9	0.23	0.96	0.31	0.65	0.59	0.97	0.75	0.51	1.0	0.75	0.95	0.57	0.6	0.33		0.9	0.71	0.82	0.91	0.89
Inventory	0.94	0.74	0.55	0.96	0.69	0.86	0.19	0.85	0.25	0.62	0.55	0.93	0.69	0.39	0.89	0.67	0.97	0.65	0.74	0.35	0.9		0.75	0.84	0.79	0.95
Other Current Assets	0.72	0.4	0.23	0.8	0.43	0.6	0.08	0.67	0.4	0.3	0.29	0.76	0.55	0.22	0.71	0.36	0.78	0.5	0.53	0.15	0.71	0.75		0.56	0.52	0.83
Other Stockholder Equity	0.84	0.74	0.56	0.81	0.61	0.93	0.38	0.81	-0.13	0.67	0.52	0.76	0.65	0.53	0.82	0.83	0.79	0.88	0.9	0.63	0.82	0.84	0.56		0.84	0.74
Total Liab	0.92	0.87	0.81	0.79	0.88	0.94	0.23	0.88	0.18	0.54	0.78	0.87	0.83	0.66	0.9	0.87	0.81	0.61	0.63	0.32	0.91	0.79	0.52	0.84		0.71
Property Plant And Equipment Gross	0.92	0.61	0.44	0.98	0.62	0.79	0.15	0.86	0.42	0.55	0.43	0.94	0.72	0.35	0.88	0.57	0.97	0.56	0.62	0.3	0.89	0.95	0.83	0.74	0.71

Click cells to compare fundamentals

Pacira Pharmaceuticals Account Relationship Matchups

Pacira Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	831.1M	1.3B	2.1B	1.7B	1.6B	1.7B
Other Current Liab	18.2M	14.7M	117.9M	89.8M	64.2M	36.3M
Total Current Liabilities	107.7M	253.3M	521.1M	147.8M	97.4M	123.5M
Total Stockholder Equity	354.9M	619.7M	730.4M	775.0M	870.1M	913.6M
Other Liab	21.5M	17.4M	77.6M	37.8M	43.5M	24.9M
Property Plant And Equipment Net	142.8M	211.2M	264.8M	254.4M	234.9M	120.3M
Net Debt	273.7M	441.2M	543.3M	659.3M	432.7M	454.4M
Retained Earnings	(399.4M)	(253.9M)	(211.9M)	(148.8M)	(106.8M)	(112.1M)
Accounts Payable	12.8M	10.4M	10.5M	15.2M	15.7M	10.4M
Cash	78.2M	100.0M	585.6M	104.1M	153.3M	117.4M
Non Current Assets Total	422.5M	622.9M	1.2B	1.2B	1.1B	1.1B
Non Currrent Assets Other	11.0M	74.5M	76.4M	27.2M	36.0M	37.9M
Other Assets	971K	290.1M	153.4M	160.3M	1.0	0.95
Long Term Debt	306.0M	313.0M	674.5M	655.8M	513.8M	539.5M
Cash And Short Term Investments	292.0M	521.7M	656.4M	288.7M	278.6M	237.8M
Net Receivables	47.5M	53.0M	96.3M	98.4M	105.6M	110.8M
Common Stock Shares Outstanding	41.5M	43.7M	45.6M	46.5M	52.0M	35.9M
Short Term Investments	213.7M	421.7M	70.8M	184.5M	125.3M	137.9M
Liabilities And Stockholders Equity	831.1M	1.3B	2.1B	1.7B	1.6B	1.7B
Non Current Liabilities Total	368.4M	401.5M	823.8M	758.4M	606.9M	637.2M
Inventory	58.3M	64.7M	98.6M	96.1M	104.4M	109.6M
Other Current Assets	10.8M	12.3M	14.8M	15.2M	21.5M	22.6M
Other Stockholder Equity	754.0M	873.2M	942.1M	924.1M	976.6M	599.8M
Total Liab	476.1M	654.8M	1.3B	906.2M	704.3M	396.5M
Property Plant And Equipment Gross	142.8M	211.2M	264.8M	254.4M	370.3M	388.8M
Total Current Assets	408.6M	651.6M	866.0M	498.3M	510.0M	331.8M
Accumulated Other Comprehensive Income	322K	318K	167K	(380K)	247K	259.4K
Short Term Debt	4.9M	157.1M	382.6M	42.8M	17.4M	16.6M
Common Stock	42K	44K	45K	46K	52.9K	35.1K
Property Plant Equipment	104.7M	136.7M	264.8M	254.4M	292.5M	307.2M
Short Long Term Debt Total	351.9M	541.1M	1.1B	763.4M	586.0M	348.5M
Net Tangible Assets	151.0M	423.6M	(38.7M)	71.2M	81.9M	77.8M
Retained Earnings Total Equity	(388.2M)	(399.4M)	(253.9M)	(211.9M)	(190.7M)	(200.2M)
Long Term Debt Total	276.2M	290.6M	306.0M	313.0M	360.0M	240.7M
Capital Surpluse	709.7M	754.0M	873.2M	942.1M	1.1B	685.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

SGC	Superior Uniform Group
VLN	Valens
GNFT	Genfit

Additional Tools for Pacira Stock Analysis

When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pacira Other Current Liab vs Common Stock Total Equity Analysis

Other Current Liab vs Common Stock Total Equity

Other Current Liab vs Common Stock Total Equity Correlation Analysis

Correlation Coefficient

Other Current Liab

Common Stock Total Equity

Pacira Pharmaceuticals fundamental ratios Correlations

Pacira Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pacira Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Pacira Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Long Term Debt
Non Current Assets Total	+ 0.98	Total Assets
Non Current Liabilities Total	+ 0.98	Total Assets
Net Receivables	+ 0.98	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.98	Total Stockholder Equity
Net Receivables	+ 0.98	Non Current Assets Total

Short Term Investments	- 0.42	Retained Earnings
Common Stock Total Equity	- 0.34	Retained Earnings
Retained Earnings	- 0.34	Current Deferred Revenue
Common Stock Shares Outstanding	- 0.32	Retained Earnings
Cash And Short Term Investments	- 0.16	Retained Earnings
Other Stockholder Equity	- 0.13	Retained Earnings